Download PDFPDF

Original article
Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address